Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer
- PMID: 12203806
- DOI: 10.1002/hed.10108
Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer
Abstract
Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including oral leukoplakia and squamous cell carcinoma of the head and neck. Increased levels of COX-2 may contribute to carcinogenesis by modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. In experimental models, newly developed selective COX-2 inhibitors suppress the formation of tumors, including tongue cancer. These findings provided a rationale for a number of chemoprevention trials that are underway. Selective COX-2 inhibitors also suppress the growth and metastases of established tumors and enhance the anticancer activity of both radiotherapy and chemotherapy in experimental animals. In this review, evidence is presented that inhibition of COX-2 represents a promising strategy to prevent or possibly treat human head and neck cancers.
Copyright 2002 Wiley Periodicals, Inc.
Similar articles
-
[Cylooxgenase-2: a novel molecular target for the prevention and treatment of head and neck cancer on the advance of basic and preclinical research].Zhonghua Kou Qiang Yi Xue Za Zhi. 2004 May;39(3):261-3. Zhonghua Kou Qiang Yi Xue Za Zhi. 2004. PMID: 15196405 Review. Chinese. No abstract available.
-
Role of COX-2 specific inhibitors in oncogenesis.J Coll Physicians Surg Pak. 2003 Jun;13(6):361-5. J Coll Physicians Surg Pak. 2003. PMID: 12814542 Review.
-
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.Cancer Res. 2002 Nov 15;62(22):6706-11. Cancer Res. 2002. PMID: 12438270
-
Role of COX-2 selective inhibitors for prevention and treatment of cancer.Pharmazie. 2005 Aug;60(8):563-70. Pharmazie. 2005. PMID: 16124396 Review.
-
COX-2: a molecular target for colorectal cancer prevention.J Clin Oncol. 2005 Apr 20;23(12):2840-55. doi: 10.1200/JCO.2005.09.051. J Clin Oncol. 2005. PMID: 15837998 Review.
Cited by
-
Targeted therapy for head and neck squamous cell carcinoma microenvironment.Front Med (Lausanne). 2023 Aug 30;10:1257898. doi: 10.3389/fmed.2023.1257898. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37711747 Free PMC article. Review.
-
Molecular pathways modulated by phytochemicals in head and neck cancer.J Cell Commun Signal. 2023 Sep;17(3):469-483. doi: 10.1007/s12079-022-00711-0. Epub 2022 Dec 1. J Cell Commun Signal. 2023. PMID: 36454443 Free PMC article. Review.
-
Epithelial-Mesenchymal Transition Associated with Head and Neck Squamous Cell Carcinomas: A Review.Cancers (Basel). 2021 Jun 17;13(12):3027. doi: 10.3390/cancers13123027. Cancers (Basel). 2021. PMID: 34204259 Free PMC article. Review.
-
Does the administration of meloxicam before head and neck radiotherapy reduce the risk of mandibular osteoradionecrosis? An animal model study.Clin Oral Investig. 2021 Jun;25(6):3739-3745. doi: 10.1007/s00784-020-03701-x. Epub 2021 Jan 2. Clin Oral Investig. 2021. PMID: 33387032
-
Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.Int J Mol Sci. 2020 Dec 3;21(23):9246. doi: 10.3390/ijms21239246. Int J Mol Sci. 2020. PMID: 33287464 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials